Tord Inghardt
AstraZeneca (Finland)(FI)AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Carbohydrate Chemistry and Synthesis, Blood Coagulation and Thrombosis Mechanisms, PI3K/AKT/mTOR signaling in cancer, Chronic Lymphocytic Leukemia Research, Receptor Mechanisms and Signaling
Most-Cited Works
- → Human target validation of phosphoinositide 3‐kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor(2012)120 cited
- → Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide(1998)92 cited
- → Structural and functional characterization of a specific antidote for ticagrelor(2015)88 cited
- → Making medicinal chemistry more effective—application of Lean Sigma to improve processes, speed and quality(2009)69 cited
- → Identification of the Binding Site for a Low-Molecular-Weight Inhibitor of Plasminogen Activator Inhibitor Type 1 by Site-Directed Mutagenesis(1998)63 cited
- → Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction(2022)36 cited
- → Biochemical and pharmacological effects of the direct thrombin inhibitor AR-H067637(2009)34 cited
- → Sideroxylonal C, a New Inhibitor of Human Plasminogen Activator Inhibitor Type-1, from the Flowers of Eucalyptus albens(1999)29 cited
- → Enzymatic resolution of substituted mandelic acids(2003)29 cited
- → Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents(2014)28 cited